Last reviewed · How we verify
NCT05491057
Treatment Patterns of Neratinib in HER2+ EBC in China
trial testing Neratinib in Breast Cancer in 500 participants. Not yet recruiting.
30 December 2025
Quick facts
| Lead sponsor | Pierre Fabre Medicament |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 30 September 2022 |
| Primary completion | 30 December 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- Neratinib — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Pierre Fabre Medicament — full company profile →
Who can join
18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a multicenter, open-label, single-arm, non-interventional study to investigate the treatment patterns of Neratinib in HER2-positive early-stage breast cancer in China
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Neratinib for HER2-positive breast cancer with an overlooked option.
Guo L, Shao W, Zhou C, Yang H, et al · · 2023 · cited 33× · PMID 37803271 · DOI 10.1186/s10020-023-00736-0
Verify or expand the search:
- PubMed search for NCT05491057
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Neratinib
Trials testing the same drug.
- NCT06813079 — Using Tumor Models to Determine Treatments · Phase 2 · not yet recruiting
- NCT05919108 — Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers · Phase 2 · recruiting
- NCT05243641 — Neratinib and Capmatinib Combination (Phase Ib/II) in Metastatic Breast Cancer and Inflammatory Breast Cancer Patients W · Phase 1, PHASE2 · terminated
- NCT04886531 — Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers · Phase 2 · recruiting
- NCT05154396 — Neratinib Dose Escalation Regimen for HER2 Positive Early Breast Cancer · Phase 2 · unknown
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Pierre Fabre Medicament trials
Trials by the same sponsor.
- NCT06690489 — An Observational Real-world Study to Evaluate the Impact of Dermatological Toxicities on the Quality of Life in Patients · completed
- NCT06669117 — FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations · Phase 1, PHASE2 · recruiting
- NCT06688370 — The Performance and Safety of Petit Drill in the French Paediatric Population: a Post-market Clinical Follow-up Study · terminated
- NCT06043817 — First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer H · Phase 1, PHASE2 · recruiting
- NCT07096206 — Characteristics and Impacts of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) in Boys: An Observational Internationa · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05491057 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pierre Fabre Medicament
- Last refreshed: 8 August 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05491057.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing